192 related articles for article (PubMed ID: 34429402)
1. TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating EZR.
Xie A; Xu X; Kuang P; Zhang L; Yu F
Cell Death Dis; 2021 Aug; 12(9):804. PubMed ID: 34429402
[TBL] [Abstract][Full Text] [Related]
2. Trafficking protein TMED3 promotes esophageal squamous cell carcinoma.
Yang Y; Liu S; Xie C; Li Q; Gao T; Liu M; Xi M; Zhao L
Biomed J; 2023 Apr; 46(2):100528. PubMed ID: 35358714
[TBL] [Abstract][Full Text] [Related]
3. Knockdown of TMED3 inhibits cell viability and migration and increases apoptosis in human chordoma cells.
Yang J; Huang H; Xiao D; Duan Y; Zheng Y; Chen Z
Int J Oncol; 2021 May; 58(5):. PubMed ID: 33760171
[TBL] [Abstract][Full Text] [Related]
4. TMED3 exerts a protumor function in non-small cell lung cancer by enhancing the Wnt/β-catenin pathway via regulation of AKT.
Zhang D; Sun L; Zhang J
Toxicol Appl Pharmacol; 2021 Dec; 433():115793. PubMed ID: 34758370
[TBL] [Abstract][Full Text] [Related]
5. TMED3 promotes hepatocellular carcinoma progression via IL-11/STAT3 signaling.
Zheng H; Yang Y; Han J; Jiang WH; Chen C; Wang MC; Gao R; Li S; Tian T; Wang J; Ma LJ; Ren H; Zhou WP
Sci Rep; 2016 Nov; 6():37070. PubMed ID: 27901021
[TBL] [Abstract][Full Text] [Related]
6. H3K27ac-activated LINC00519 promotes lung squamous cell carcinoma progression by targeting miR-450b-5p/miR-515-5p/YAP1 axis.
Ye P; Lv X; Aizemaiti R; Cheng J; Xia P; Di M
Cell Prolif; 2020 May; 53(5):e12797. PubMed ID: 32297697
[TBL] [Abstract][Full Text] [Related]
7. TMED3 stabilizes SMAD2 by counteracting NEDD4-mediated ubiquitination to promote ovarian cancer.
Chen X; Zhang W; Han X; Li X; Xia L; Wu Y; Zhou Y
Mol Carcinog; 2024 May; 63(5):803-816. PubMed ID: 38411267
[TBL] [Abstract][Full Text] [Related]
8. PD-L1 promotes tumor growth and progression by activating WIP and β-catenin signaling pathways and predicts poor prognosis in lung cancer.
Yu W; Hua Y; Qiu H; Hao J; Zou K; Li Z; Hu S; Guo P; Chen M; Sui S; Xiong Y; Li F; Lu J; Guo W; Luo G; Deng W
Cell Death Dis; 2020 Jul; 11(7):506. PubMed ID: 32632098
[TBL] [Abstract][Full Text] [Related]
9. L1CAM drives oncogenicity in esophageal squamous cell carcinoma by stimulation of ezrin transcription.
Guo JC; Xie YM; Ran LQ; Cao HH; Sun C; Wu JY; Wu ZY; Liao LD; Zhao WJ; Fang WK; Li EM; Xu LY; Schachner M; Xie JJ
J Mol Med (Berl); 2017 Dec; 95(12):1355-1368. PubMed ID: 28939985
[TBL] [Abstract][Full Text] [Related]
10. miR-223-5p Suppresses OTX1 to Mediate Malignant Progression of Lung Squamous Cell Carcinoma Cells.
Lu Y
Comput Math Methods Med; 2021; 2021():6248793. PubMed ID: 34306176
[TBL] [Abstract][Full Text] [Related]
11. Protocadherin alpha 3 inhibits lung squamous cell carcinoma metastasis and epithelial-mesenchymal transition.
Tao Y; Fei L; Chang L; Yongyu L; Jianhui J; Yanan L; Yi R
Genes Genomics; 2022 Feb; 44(2):211-218. PubMed ID: 34086268
[TBL] [Abstract][Full Text] [Related]
12. Long non‑coding RNA LINC01748 exerts carcinogenic effects in non‑small cell lung cancer cell lines by regulating the microRNA‑520a‑5p/HMGA1 axis.
Tan Y; Xu F; Xu L; Cui J
Int J Mol Med; 2022 Feb; 49(2):. PubMed ID: 34970695
[TBL] [Abstract][Full Text] [Related]
13. LncRNA MIR9-3HG enhances LIMK1 mRNA and protein levels to contribute to the carcinogenesis of lung squamous cell carcinoma via sponging miR-138-5p and recruiting TAF15.
Xiong Y; Yang C; Yang X; Ding C; Wang Q; Zhu H
Pathol Res Pract; 2022 Sep; 237():153941. PubMed ID: 35933883
[TBL] [Abstract][Full Text] [Related]
14. MIR205HG acts as a ceRNA to expedite cell proliferation and progression in lung squamous cell carcinoma via targeting miR-299-3p/MAP3K2 axis.
Liu L; Li Y; Zhang R; Li C; Xiong J; Wei Y
BMC Pulm Med; 2020 Jun; 20(1):163. PubMed ID: 32513149
[TBL] [Abstract][Full Text] [Related]
15. LncRNA HHIP-AS1 suppresses lung squamous cell carcinoma by stabilizing HHIP mRNA.
Hu Z; Liu Y; Tang J; Luo R; Qin J; Mo Z; Xie J; Jiang X; Wei S; Lin C
Life Sci; 2023 May; 321():121578. PubMed ID: 36958438
[TBL] [Abstract][Full Text] [Related]
16. SMYD3 stimulates EZR and LOXL2 transcription to enhance proliferation, migration, and invasion in esophageal squamous cell carcinoma.
Zhu Y; Zhu MX; Zhang XD; Xu XE; Wu ZY; Liao LD; Li LY; Xie YM; Wu JY; Zou HY; Xie JJ; Li EM; Xu LY
Hum Pathol; 2016 Jun; 52():153-63. PubMed ID: 26980013
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA RP11-283G6.5 confines breast cancer development through modulating miR-188-3p/TMED3/Wnt/β-catenin signalling.
Pei J; Zhang S; Yang X; Han C; Pan Y; Li J; Wang Z; Sun C; Zhang J
RNA Biol; 2021 Oct; 18(sup1):287-302. PubMed ID: 34130584
[TBL] [Abstract][Full Text] [Related]
18. Targeted knockdown of IQGAP1 inhibits the progression of esophageal squamous cell carcinoma in vitro and in vivo.
Wang XX; Wang K; Li XZ; Zhai LQ; Qu CX; Zhao Y; Liu ZR; Wang HZ; An QJ; Jing LW; Wang XH
PLoS One; 2014; 9(5):e96501. PubMed ID: 24800852
[TBL] [Abstract][Full Text] [Related]
19. The expression, significance and function of cancer susceptibility candidate 9 in lung squamous cell carcinoma: A bioinformatics and in vitro investigation.
Gao L; Guo YN; Zeng JH; Ma FC; Luo J; Zhu HW; Xia S; Wei KL; Chen G
Int J Oncol; 2019 May; 54(5):1651-1664. PubMed ID: 30896821
[TBL] [Abstract][Full Text] [Related]
20. GNA13 promotes the proliferation and migration of lung squamous cell carcinoma cells through regulating the PI3K/AKT signaling pathway.
Na J; Zhou W; Yin M; Hu Y; Ma X
Tissue Cell; 2022 Jun; 76():101795. PubMed ID: 35413491
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
